Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


26.06.2017

2 BJU Int
2 BMC Urol
1 Br J Cancer
1 Eur J Radiol
4 Eur Urol
1 Int J Oncol
1 Int J Urol
1 J Clin Oncol
3 J Nucl Med
10 J Urol
1 Oncology (Williston Park)
3 PLoS One
1 Prog Urol
2 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Text format     Abstract available

  2. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.
    PubMed     Text format    


    BMC Urol

  3. YASHI M, Nukui A, Tokura Y, Takei K, et al
    Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
    BMC Urol. 2017;17:47.
    PubMed     Text format     Abstract available

  4. ALBAUGH JA, Sufrin N, Lapin BR, Petkewicz J, et al
    Life after prostate cancer treatment: a mixed methods study of the experiences of men with sexual dysfunction and their partners.
    BMC Urol. 2017;17:45.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. GOTO Y, Kurozumi A, Arai T, Nohata N, et al
    Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Eur J Radiol

  6. PARK SY, Shin SJ, Jung DC, Cho NH, et al
    PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer.
    Eur J Radiol. 2017;91:22-28.
    PubMed     Text format     Abstract available


    Eur Urol

  7. D'ANDREA D, Shariat SF
    Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Jun 20. pii: S0302-2838(17)30513.
    PubMed     Text format    

  8. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relations
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30504.
    PubMed     Text format    

  9. GANDAGLIA G, Boorjian SA, Parker WP, Zaffuto E, et al
    Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Eur Urol. 2017 Jun 13. pii: S0302-2838(17)30496.
    PubMed     Text format     Abstract available

  10. TREE AC, Siva S, Ost P
    Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3.
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30506.
    PubMed     Text format    


    Int J Oncol

  11. CHEN W, Liu Y, Chen H, Ning H, et al
    Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.
    Int J Oncol. 2017 Jun 12. doi: 10.3892/ijo.2017.4038.
    PubMed     Text format     Abstract available


    Int J Urol

  12. NOGUCHI M, Koga N, Igawa T, Itoh K, et al
    Clinical development of immunotherapy for prostate cancer.
    Int J Urol. 2017 Jun 21. doi: 10.1111/iju.13397.
    PubMed     Text format     Abstract available


    J Clin Oncol

  13. ANTONARAKIS ES, Tagawa ST, Galletti G, Worroll D, et al
    Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Jun 20:JCO2017724138. doi: 10.1200/JCO.2017.72.4138.
    PubMed     Text format     Abstract available


    J Nucl Med

  14. HOFMAN MS
    Accuracy in the eye of the beholder: can we improve agreement in prostate cancer diagnostics with PSMA PET/CT?
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.192542. doi: 10.2967/jnumed.117.192542.
    PubMed     Text format    

  15. VINSENSIA M, Choyke PL, Hadaschik B, Holland-Letz T, et al
    68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.116.185033. doi: 10.2967/jnumed.116.185033.
    PubMed     Text format     Abstract available

  16. ROACH PJ, Francis R, Emmett L, Hsiao E, et al
    The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.
    J Nucl Med. 2017 Jun 23. pii: jnumed.117.197160. doi: 10.2967/jnumed.117.197160.
    PubMed     Text format     Abstract available


    J Urol

  17. TANEJA SS
    Re: Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    J Urol. 2017;198:100-102.
    PubMed     Text format    

  18. TANEJA SS
    Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    J Urol. 2017;198:101-102.
    PubMed     Text format    

  19. ATALA A
    Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance.
    J Urol. 2017;198:102-104.
    PubMed     Text format    

  20. ATALA A
    Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
    J Urol. 2017;198:103.
    PubMed     Text format    

  21. ATALA A
    Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer.
    J Urol. 2017;198:103-104.
    PubMed     Text format    

  22. PENSON DF
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Urol. 2017;198:104-106.
    PubMed     Text format    

  23. PENSON DF
    Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
    J Urol. 2017;198:104-105.
    PubMed     Text format    

  24. KIBEL AS
    Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  25. PALAPATTU GS
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  26. PUNNEN S, Parekh DJ
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67197-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    Oncology (Williston Park)

  27. AGGARWAL RR, Feng FY, Small EJ
    Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
    Oncology (Williston Park). 2017;31:467-74.
    PubMed     Text format     Abstract available


    PLoS One

  28. RIVERA M, Ramos Y, Rodriguez-Valentin M, Lopez-Acevedo S, et al
    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells.
    PLoS One. 2017;12:e0179587.
    PubMed     Text format     Abstract available

  29. DELOBEL JB, Gnep K, Ospina JD, Beckendorf V, et al
    Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    PLoS One. 2017;12:e0179845.
    PubMed     Text format     Abstract available

  30. ZEDAN AH, Blavnsfeldt SG, Hansen TF, Nielsen BS, et al
    Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    PLoS One. 2017;12:e0179113.
    PubMed     Text format     Abstract available


    Prog Urol

  31. MARIEN A, De Castro Abreu A, Gill I, Villers A, et al
    [Interest using 3D ultrasound and MRI fusion biopsy for prostate cancer detection].
    Prog Urol. 2017 Jun 16. pii: S1166-7087(17)30130.
    PubMed     Text format     Abstract available


    Prostate

  32. CAI B, Chen W, Pan Y, Chen H, et al
    Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
    PubMed     Text format     Abstract available

  33. HE C, Duan S, Dong L, Wang Y, et al
    Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
    PubMed     Text format     Abstract available


    Urology

  34. MANNAS M, Chedgy E, Black PC
    You Pays Your Money, You Takes Your Choice: Functional Outcomes Following Curative Treatment for Clinically Localized Prostate Cancer.
    Urology. 2017 Jun 15. pii: S0090-4295(17)30625.
    PubMed     Text format    

  35. GORIN MA, Pienta KJ, Pomper MG, Rowe SP, et al
    Prostate Cancer Local Recurrence Detected with Both 18F-Fluciclovine and PSMA-Targeted 18F-DCFPyL PET/CT.
    Urology. 2017 Jun 19. pii: S0090-4295(17)30635.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: